Eli Lilly and Company discovers develops and markets human pharmaceuticals worldwide. The company offers Basaglar Humalog Humalog Mix 75/25 Humalog U-100 Humalog U-200 Humalog Mix 50/50 insulin lispro insulin lispro protamine insulin lispro mix 75/25 Humulin Humulin 70/30 Humulin N Humulin R and Humulin U-500 for diabetes; Jardiance Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products including Alimta Cyramza Erbitux Jaypirca Retevmo Tyvyt and Verzenio. In addition the company offers Olumiant for rheumatoid arthritis atopic dermatitis severe alopecia areata and COVID-19; Taltz for plaque psoriasis psoriatic arthritis ankylosing spondylitis and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder diabetic peripheral neuropathic pain generalized anxiety disorder fibromyalgia and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC) a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states including diabetes obesity cardiovascular diseases neurodegeneration and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals Inc.; F. Hoffmann-La Roche Ltd and Genentech Inc.; Biologics Inc. AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co. Ltd as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis Indiana.